Application of Artificial Neural Networks for Decision Support in Medicine

  • Brendan LarderEmail author
  • Dechao Wang
  • Andy Revell
Part of the Methods in Molecular Biology™ book series (MIMB, volume 458)


The emergence of drug resistant pathogens can reduce the efficacy of drugs commonly used to treat infectious diseases. Human immunodeficiency virus (HIV) is particularly sensitive to drug selection pressure, rapidly evolving into drug resistant variants on exposure to anti-HIV drugs. Over 200 mutations within the genetic material of HIV have been shown to be associated with drug resistance to date, and complex mutational patterns have been found in HIV isolates from infected patients exposed to multiple antiretroviral drugs. Genotyping is commonly used in clinical practice as a tool to identify drug resistance mutations in HIV from individual patients. This information is then used to help guide the choice of future therapy for patients whose drug regimen is failing because of the development of drug resistant HIV. Many sets of rules and algorithms are available to predict loss of susceptibility to individual antiretroviral drugs from genotypic data. Although this approach has been helpful, the interpretation of genotypic data remains challenging. We describe here the development and application of ANN models as alternative tools for the interpretation of HIV genotypic drug resistance data.

A large amount of clinical and virological data, from around 30,000 patients treated with antiretroviral drugs, has been collected by the HIV Resistance Response Database Initiative (RDI, in a centralized database. Treatment change episodes (TCEs) have been extracted from these data and used along with HIV drug resistance mutations as the basic input variables to train ANN models. We performed a series of analyses that have helped define the following: (1) the reliability of ANN predictions for HIV patients receiving routine clinical care; (2) the utility of ANN models to identify effective treatments for patients failing therapy; (3) strategies to increase the accuracy of ANN predictions; and (4) performance of ANN models in comparison to the rules-based methods currently in use.


Artificial neural networks decision support HIV infection clinical response antiretroviral therapy. 


  1. 1.
    Ahmed FE (2005) Artificial neural networks for diagnosis and survival prediction in colon cancer. Mol Cancer 4:29–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, et al. (2005) Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat 94:265–272.CrossRefPubMedGoogle Scholar
  3. 3.
    Anagnostou T, Remzi M, Lykourinas M, Djavan B (2003) Artificial neural networks for decision-making in urologic oncology. Eur Urol 43:596–603.PubMedGoogle Scholar
  4. 4.
    Suzuki K, Li F, Sone S, Doi K (2005) Computer-aided diagnostic scheme for distinction between benign and malignant nodules in thoracic low-dose CT by use of massive training artificial neural network. IEEE Trans Med Imaging 24:1138–1150.CrossRefPubMedGoogle Scholar
  5. 5.
    Baxt WG, Shofer FS, Sites FD, Hollander JE (2002) A neural computational aid to the diagnosis of acute myocardial infarction. Ann Emerg Med 39:366–373.CrossRefPubMedGoogle Scholar
  6. 6.
    George J, Ahmed A, Patnaik M, Adler Y, Levy Y, Harats D, et al. (2000) The prediction of coronary atherosclerosis employing artificial neural networks. Clin Cardiol 23:453–456.CrossRefPubMedGoogle Scholar
  7. 7.
    Zini G (2005) Artificial intelligence in hematology. Hematology 10:393–400.CrossRefPubMedGoogle Scholar
  8. 8.
    Solomon I, Maharshak N, Chechik G, Leibovici L, Lubetsky A, Halkin H, et al. (2004) Applying an artificial neural network to warfarin maintenance dose prediction. Isr Med Assoc J 6:732–735.PubMedGoogle Scholar
  9. 9.
    Huang L, Yu P, Ju F, Cheng J (2003) Prediction of response to incision using the mutual information of electroencephalograms during anaesthesia. Med Eng Phys 25:321–327.CrossRefPubMedGoogle Scholar
  10. 10.
    Fuller J J, Emmett M, Kessel JW, Price PD, Forsythe, J. H. (2005) A comparison of neural networks for computing predicted probability of survival for trauma victims. WV Med J 101:120–125.Google Scholar
  11. 11.
    Bent P, Tan HK, Bellomo R, Buckmaster J, Doolan L, Hart G, et al. (2001) Early and intensive continuous hemofiltration for severe renal failure after cardiac surgery. Ann Thorac Surg 71:832–837.CrossRefPubMedGoogle Scholar
  12. 12.
    Papik K, Molnar B, Schaefer R, Dombovari Z, Tulassay Z, Feher J (1995) Application of neural networks in medicine: a review. Diagnostics and Medical Technology 1:538–546.Google Scholar
  13. 13.
    Zhu Y, Williams S, Zwiggelaar R (2006) Computer technology in detection and staging of prostate carcinoma: a review. Med Image Anal 10:178–199.CrossRefPubMedGoogle Scholar
  14. 14.
    Lisboa PJ, Taktak AF (2006) The use of artificial neural networks in decision support in cancer: a systematic review. Neural Netw (Feb 13) (Epub in press).Google Scholar
  15. 15.
    Crawford ED (2003) Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks. Urology 62 (6) Suppl 1:13–19.CrossRefPubMedGoogle Scholar
  16. 16.
    Koss LG, Sherman, ME, Cohen MB, Anes AR, Darragh TM, Lemos LB, et al. (1997) Significant reduction in the rate of false-negative cervical smears with neural network-based technology (PAPNET testing system). Hum Pathol 28:1196–1203.CrossRefPubMedGoogle Scholar
  17. 17.
    Sherman ME, Schiffman MH, Mango LJ, Kelly D, Acosta D, Cason Z, et al. (1997) Evaluation of PAPNET testing as an ancillary tool to clarify the status of the “atypical” cervical smear. Mod Pathol10:564–571.PubMedGoogle Scholar
  18. 18.
    Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, et al. (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56:1000–1006.CrossRefPubMedGoogle Scholar
  19. 19.
    Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B (2003) An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml or less. J Urol 169:1724–1728.CrossRefPubMedGoogle Scholar
  20. 20.
    Egmont-Petersen M, de Ridder D, Handels H (2002) Image processing with neural networks-a review. Pattern Recognition 35:2279–2301.CrossRefGoogle Scholar
  21. 21.
    Sordo M (2002) Introduction to neural networks in healthcare. Open Clinical. [online]
  22. 22.
    Wang D, Larder B (2003) Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 188:653–660.CrossRefPubMedGoogle Scholar
  23. 23.
    The Panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Social Services. (2006) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, October 6, 2005. [online]
  24. 24.
    Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191:339–347.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang D, De Gruttola V, Hammer S, Harrigan R, Larder B, Wegner S, et al., on Behalf of the HIV Resistance Response Database Initiative. (2002). A collaborative HIV resistance response database initiative: predicting virological response using neural network models. Antiviral Therapy 7:S96.Google Scholar
  26. 26.
    Wang D, Larder BA, Revell A, Harrigan R, Montaner J, on behalf of the HIV Resistance Response Database Initiative. (2003). A neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures. Antiviral Therapy 8:S112.Google Scholar
  27. 27.
    Larder BA, Wang D, Revell A, Lane C (2003) Neural network model identified potentially effective drug combinations for patients failing salvage therapy. 2nd IAS conference on HIV pathogenesis and treatment, Paris, July 13–16, poster LB39.Google Scholar
  28. 28.
    Larder BA, Wang D, Revell A, Harrigan R, Montaner J, Lane C (2004) Accuracy of neural network models in predicting HIV treatment response from genotype may depend on diversity as well as size of data sets. 11th conference on retroviruses and opportunistic infections, San Francisco, February 8–11, poster 697.Google Scholar
  29. 29.
    Revell A, Larder BA, Wang D, Wegner S, Harrigan R, Montaner J, Lane C (2005) Global neural network models are superior to single clinic models as general quantitative predictors of virologic treatment response. 3rd IAS conference on HIV pathogenesis and treatment. July 24–27, Rio de Janeiro, poster WePe12.6C04.Google Scholar
  30. 30.
    Wang D, Larder BA, Revell A, Harrigan R, Montaner J, Wegner S, Lane C (2005) Treatment history improves the accuracy of neural networks predicting virologic response to HIV therapy. BioSapiens-viRgil workshop on bioinformatics for viral infections, September 21–23, Caesar Bonn, Germany, poster 20.Google Scholar
  31. 31.
    Larder BA, Wang D, Revell A, Harrigan R, Montaner J,Wegner S, Lane C (2005) Treatment history but not previous genotype improves the accuracy of predicting virologic response to HIV therapy. 45th ICAAC, December 16–19. Washington, DC, poster H-1051.Google Scholar
  32. 32.
    Larder BA, Wang D, Revell A, Harrigan R, Montaner J, Wegner S, Lane C (2005). Treatment history and adherence information significantly improves prediction of virological response by neural networks. Antiviral Therapy 10:S57.Google Scholar
  33. 33.
    Larder BA, Revell A, Wang D, Harrigan R, Montaner J, Wegner S, Lane C (2005) Neural networks are more accurate predictors of virological response to HAART than rules-based genotype interpretation systems. 10th European AIDS conference/EACS, November 17–20, Dublin, poster PE3.4/13Google Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2008

Authors and Affiliations

  1. 1.HIV Resistance Response Database Initiative (RDI)London, N1 7DHUK
  2. 2.HIV Resistance Response Database Initiative (RDI)LondonUK

Personalised recommendations